HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.